Form 4: Heron Therapeutics Executive William Forbes Reports Stock Unit Vesting
SEC Form 4 Filing
William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, reports the vesting of restricted stock units into common stock.
Summary
- On April 19, 2024, William P. Forbes, EVP and Chief Development Officer of Heron Therapeutics, reported the vesting of 3,874 restricted stock units into common stock.
- This transaction increased his direct holdings to 82,874 shares of common stock.
- The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the grant date of January 19, 2024.
- Forbes also has a Power of Attorney appointing Kathryn Lester to execute and file Forms 3, 4, and 5 on his behalf.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation and does not indicate any significant positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the normal vesting of previously granted equity compensation.
Stakeholder Impact
- The vesting of stock units has a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/08/2024 | Date of Power of Attorney execution. |
| 01/19/2024 | Grant date of restricted stock units. |
| 04/19/2024 | Date of transaction (vesting of restricted stock units). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.